Pre-made Loncastuximab Tesirine benchmark antibody (Whole mAb ADC, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Loncastuximab Tesirine benchmark antibody (Whole mAb ADC, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Loncastuximab tesirine , sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma.[1] It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-896-1mg	1mg	Inquiry
GMP-Bios-INN-896-10mg	10mg	Inquiry
GMP-Bios-INN-896-100mg	100mg	Inquiry
GMP-Bios-INN-896-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Loncastuximab Tesirine Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugate
INN Name	Loncastuximab Tesirine
Target	CD19
Format	Whole mAb ADC
Derivation	Chimeric
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	ADC Therapeutics (Epalinges Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0